Markets3 min read

Cannabis Stocks Rally as MSOS Hits $5.66, Trulieve Climbs to $11.74

Major cannabis equities surge Monday with MSOS ETF gaining ground alongside individual operator strength across the sector.

June 8, 2026 at 2:56 PMCannabismarketcap

Cannabis equities posted broad-based gains Monday, with the AdvisorShares Pure US Cannabis ETF (MSOS) advancing to $5.66 while Trulieve Cannabis reached $11.74 during intraday trading. The coordinated upward movement across multiple operators signals renewed investor confidence in the sector's near-term prospects.

ETF Performance Drives Sector Momentum

MSOS continues to serve as the primary barometer for institutional cannabis exposure, with Monday's advance representing meaningful progress for the fund that has struggled with volatility throughout 2024. The ETF's climb to $5.66 reflects underlying strength across its top holdings, which include major multi-state operators that have demonstrated operational resilience despite regulatory headwinds.

The fund's performance carries particular weight given its $400 million in assets under management and its role as the largest pure-play cannabis ETF in the market. Institutional flows into MSOS often precede broader sector rallies, making Monday's gains a potential catalyst for sustained momentum.

Individual Operator Strength

Trulieve's advance to $11.74 underscores the company's position as a dominant force in Florida's medical cannabis market, where the operator maintains approximately 53% market share. The stock's performance reflects investor confidence in the company's ability to navigate potential adult-use expansion in Florida, particularly as Amendment 3 ballot initiatives gain traction ahead of November elections.

The coordinated gains across cannabis stocks suggest investors are positioning ahead of potential regulatory developments at both state and federal levels. Several operators have reported strong Q2 preliminary results, with many posting sequential revenue growth despite challenging market conditions in key states like California and Illinois.

Regulatory Backdrop Supports Optimism

Monday's rally occurs against a backdrop of evolving federal cannabis policy, with Schedule III rescheduling discussions continuing to influence investor sentiment. The Drug Enforcement Administration's ongoing review process has created anticipation for potential tax relief under Section 280E, which currently prevents cannabis operators from deducting standard business expenses.

State-level developments also contribute to the positive sentiment, with Pennsylvania and Ohio advancing adult-use programs while Florida prepares for a pivotal November vote on recreational cannabis. These expansion opportunities represent significant revenue potential for established operators with existing infrastructure and capital resources.

Market Technical Factors

The broad-based nature of Monday's advance suggests technical buying pressure as several cannabis stocks approach key resistance levels. MSOS has been consolidating near current levels for several weeks, with $5.66 representing a break above recent trading ranges that could attract momentum-driven investors.

Volume patterns across individual cannabis stocks indicate genuine institutional interest rather than retail-driven speculation. This distinction matters for sector sustainability, as institutional participation typically provides more stable price support during market volatility.

Sector Outlook and Investment Implications

The cannabis industry enters the second half of 2024 with improved operational metrics across most major operators, despite ongoing challenges from state-level oversupply in mature markets. Companies with strong balance sheets and diversified geographic exposure continue to outperform single-state operators, reflecting investor preference for scale and financial stability.

Cannabis operators with established market positions and expansion capital are best positioned to capitalize on new state markets and potential federal regulatory changes.

Monday's gains reinforce the sector's sensitivity to both regulatory developments and broader market sentiment. As cannabis companies prepare to report Q2 earnings over the coming weeks, investor focus will shift to revenue growth sustainability and margin improvement initiatives across the industry's leading operators.